Research Article

Comparison of the E test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Isolated from Blood Cultures

Volume: 21 Number: 2 April 1, 2017
EN TR

Comparison of the E test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Isolated from Blood Cultures

Abstract

Increased resistance against antifungal agents recently shows the
importance of antifungal susceptibility testing especially to Candida
spp. isolated from invasive infections. Although the Broth Microdilution
(BMD) method has been standardized as an antifungal susceptibility
testing by “Clinical and Laboratory Standards Institute (CLSI)”,
difficulties in the practice of the this method pushed the researchers to
seek more practical methods that can be used in routine laboratories.
The aim of this study was to compare E-test method with standard
BMD method for antifungal susceptibility testing of Candida spp.
isolated from blood cultures in our hospital, against fluconazole which
is commonly used in the treatment of systemic Candida infections. In
addition by the distribution of the accumulated isolates in the process
of the study, the most common species of Candida causes Candidemia
in our hospital were determined.
74 Candida strains (49 C. albicans, 15 C.parapsilosis, 6 C.tropicalis, 4 C.
glabrata) isolated from blood cultures (BACTEC 9000 System, Becton
Dickinson ®) sent from various clinics to Ataturk University Hospital
Medical Microbiology Laboratory between April 2012-December 2015
were included in the study. Chromogenic agar, automated VITEK
2 system (BioMerieux®, France) and if necessary the morphological
appearance on Corn Meal Agar with Tween® 80 were used to identify
Candida spp. Fluconazole susceptibility of Candida species were
determined by standard BMD method defined by CLSI and E test
method.
While 49 of the 74 isolated strains (66.2%) were albicans, 25 of them
(33.8%) were found to be non-albicans species. The most frequently
non-albicans species were C.parapsilosis (20.2%). According to the
MIC values, no fluconazole resistance was interpreted for C.albicans
and C.glabrata by both methods. However, 2 of 15 C.parapsilosis strains
were interpreted as resistant to floconazole with both methods and 2 of
6 C.tropicalis strains were interpreted as resistant with E test method.
While one of the same C.tropicalis strains was interpreted as susceptible,
the other one was interpreted as susceptible-dose dependence (S-DD)
with BMD method. According to these findings the total resistance rate
of Candida species was 5.4% by E test method while it was determined
as 2.7% in BMD method. In C.tropicalis species the result which
was resistance by E test method and sensistive by BMD method was
evaluated as “major error” (ME); the result which was resistance by E
test method and susceptible-dose dependence (S-DD) by BMD method
was evaluated as “minor error” (mE). Any “very major error” (VME)
was not found and the total agreement (EA) was calculated as 85.1%
in the study.
According to our results that can be suggested E test method can be
used as an alternative antifungal susceptibility test in routine laboratory.
However, although the E test method is easy to use and has high
reproducibility advantage compared with the BMD method, it requires
attention and experience in the application and interpretation phases of
antifungal susceptibility testing.

Keywords

References

  1. 1. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R,Viscoli C. Epidemiological trends in nosocomial candidemiain intensive care. BMC Infect Dis 2006; 6: 1.
  2. 2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, WenzelRP,Edmond MB. Nosocomial bloodstream infections inUS hospitals: analysis of 24,179 cases from a prospectivenationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
  3. 3. Yapar N. Epidemiology and risk factors for invasivecandidiasis. Ther Clin Risk Manag 2014; 10: 95-105.
  4. 4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis:a persistent public health problem. Clin Microbiol Rev 2007;20: 133-63.
  5. 5. Sievert DM, Rick P, Edwards JR, Schneider A, Patel J, SrinivasanA, Fridkin S. National Healthcare Safety Network (NHSN)Team and Participating NHSN Facilities. Antimicrobialresistantpathogens associated with healthcare-associatedinfections: summary of data reported to the NationalHealthcare Safety Network at the Centers for Disease Controland Prevention, 2009-2010. Infect Control Hosp Epidemiol2013; 34: 1-14.
  6. 6. Tortorano AM, Peman J, Bernhardt H, Klingspor L, KibblerCC, Faure O, Grillot R. Epidemiology of candidaemia inEurope: Results of 28-month European Confederation ofMedical Mycology (ECMM) hospital-based surveillancestudy. Eur J CliN MicrobioL Infect Dis 2004; 23: 317-22.
  7. 7. Hospenthal DR, Murray CK, Rinaldi MG. The role ofantifungal susceptibility testing in the therapy of candidiasis.Diagn Microbiol Infect Dis 2004; 48: 153-60.
  8. 8. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA,Ostrosky-Zeichner L, Zaoutis TE. Clinical practice guidelinefor the management of candidiasis: 2016 update by theInfectious Diseases Society of America. Clin Infect Dis 2015;4: 933.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

İclal Ağan This is me

M. Hamidullah Uyanık This is me

Hayrünisa Hancı This is me

Kemalettin Özden This is me

Publication Date

April 1, 2017

Submission Date

January 6, 2017

Acceptance Date

-

Published in Issue

Year 2017 Volume: 21 Number: 2

APA
Coşkun, M. V., Ağan, İ., Uyanık, M. H., Hancı, H., & Özden, K. (2017). Comparison of the E test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Isolated from Blood Cultures. Marmara Pharmaceutical Journal, 21(2), 400-406. https://doi.org/10.12991/marupj.301167
AMA
1.Coşkun MV, Ağan İ, Uyanık MH, Hancı H, Özden K. Comparison of the E test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Isolated from Blood Cultures. J Res Pharm. 2017;21(2):400-406. doi:10.12991/marupj.301167
Chicago
Coşkun, Mehmet Veysel, İclal Ağan, M. Hamidullah Uyanık, Hayrünisa Hancı, and Kemalettin Özden. 2017. “Comparison of the E Test With the CLSI Broth Microdilution Reference Method for Testing Fluconazole Against Candida Spp. Isolated from Blood Cultures”. Marmara Pharmaceutical Journal 21 (2): 400-406. https://doi.org/10.12991/marupj.301167.
EndNote
Coşkun MV, Ağan İ, Uyanık MH, Hancı H, Özden K (May 1, 2017) Comparison of the E test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Isolated from Blood Cultures. Marmara Pharmaceutical Journal 21 2 400–406.
IEEE
[1]M. V. Coşkun, İ. Ağan, M. H. Uyanık, H. Hancı, and K. Özden, “Comparison of the E test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Isolated from Blood Cultures”, J Res Pharm, vol. 21, no. 2, pp. 400–406, May 2017, doi: 10.12991/marupj.301167.
ISNAD
Coşkun, Mehmet Veysel - Ağan, İclal - Uyanık, M. Hamidullah - Hancı, Hayrünisa - Özden, Kemalettin. “Comparison of the E Test With the CLSI Broth Microdilution Reference Method for Testing Fluconazole Against Candida Spp. Isolated from Blood Cultures”. Marmara Pharmaceutical Journal 21/2 (May 1, 2017): 400-406. https://doi.org/10.12991/marupj.301167.
JAMA
1.Coşkun MV, Ağan İ, Uyanık MH, Hancı H, Özden K. Comparison of the E test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Isolated from Blood Cultures. J Res Pharm. 2017;21:400–406.
MLA
Coşkun, Mehmet Veysel, et al. “Comparison of the E Test With the CLSI Broth Microdilution Reference Method for Testing Fluconazole Against Candida Spp. Isolated from Blood Cultures”. Marmara Pharmaceutical Journal, vol. 21, no. 2, May 2017, pp. 400-6, doi:10.12991/marupj.301167.
Vancouver
1.Mehmet Veysel Coşkun, İclal Ağan, M. Hamidullah Uyanık, Hayrünisa Hancı, Kemalettin Özden. Comparison of the E test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Isolated from Blood Cultures. J Res Pharm. 2017 May 1;21(2):400-6. doi:10.12991/marupj.301167

.